CMS is aiming to make Medicare Part D formulary prior authorization practices more clear and consistent by proposing new requirements for drug plans in its draft "call letter" to prospective plan sponsors for the 2009 benefit year
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.
Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.
